Compare Estee Lauder Companies Inc (EL) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Estee Lauder Companies Inc vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? Estee Lauder Companies Inc trades at $101.67 (market cap $36.81B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $977.37M). The key difference: Estee Lauder Companies Inc is far larger — about 37.7× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Estee Lauder Companies Inc pays a 1.38% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Estee Lauder Companies Inc for 123 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| EL | MRVI | |
|---|---|---|
Market Cap | $36.81B | $977.37M |
Volume | 2,214,573 | 2,742,564 |
Sector | Consumer Staples | Health |
52-Week High | $119.61 | $9.00 |
52-Week Low | $67.23 | $2.83 |
Typical Hold Time | 123 Days | 0 Days |
Enterprise Value | $42.56B | $1.08B |
Dividend Yield | 1.38% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Estée Lauder (EL) trades at $99.73, down 0.31% on the day, with a bullish technical signal supported by moving averages. The company shows mixed fundamentals with a high P/E ratio of 199.46 but strong gross margins of 75.5%. Recent earnings beats and a strategic AI partnership with Profound highlight operational momentum, though 2025 saw a net loss of $1.13B. Analyst consensus is positive with a $103 price target and 48% buy ratings.
The outlook remains cautiously optimistic as EL navigates margin recovery and digital transformation. Key opportunities include brand innovation and AI integration, while risks involve persistent profitability challenges and competitive pressures. The stock's current level near resistance at $102 suggests near-term consolidation potential.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Estee Lauder Companies Inc
Estee Lauder is the world leader in the global prestige beauty market, participating across skincare (56% of fiscal 2022 sales), makeup (26%), fragrance (14%), and haircare (4%) categories, with popular brands such as Estee Lauder, Clinique, MAC, La Mer, Jo Malone, Aveda, Bobbi Brown, Too Faced, Origins, Dr. Jart+, and The Ordinary. The firm operates in 150 countries, with 26% of fiscal 2022 revenue stemming from the Americas, 43% from Europe, the Middle East, and Africa, and 31% from Asia-Pacific. The company sells its products through department stores, travel retail, multi-brand specialty beauty stores, brand-dedicated freestanding stores, e-commerce, salons/spas, and perfumeries.
Read more on EL →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
